Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 10.

Greuter, T; Biedermann, L; Rogler, G; Sauter, B; Seibold, F (2016). Alicaforsen, an antisense inhibitor of ICAM-1, as treatment for chronic refractory pouchitis after proctocolectomy: A case series. United European Gastroenterology journal, 4(1):97-104.

Safroneeva, E; Vavricka, S; Fournier, N; Seibold, F; Mottet, C; Nydegger, A; Ezri, J; Straumann, A; Rogler, G; Schoepfer, A M; Braegger, C; Swiss IBD Cohort Study Group (2015). Systematic analysis of factors associated with progression and regression of ulcerative colitis in 918 patients. Alimentary Pharmacology & Therapeutics, 42(5):540-548.

Seibold, F; Fournier, N; Beglinger, C; Mottet, C; Pittet, V; Rogler, G (2014). Topical therapy is underused in patients with ulcerative colitis. Journal of Crohn's & colitis, 8(1):56-63.

Vavricka, S R; Schoepfer, A M; Bansky, G; Binek, J; Felley, C; Geyer, M; Manz, M; Rogler, G; de Saussure, P; Sauter, B; Scharl, M; Seibold, F; Straumann, A; Michetti, P (2011). Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey. Inflammatory Bowel Diseases, 17(7):1530-1539.

Schoepfer, A M; Vavricka, S R; Binek, J; Felley, C; Geyer, M; Manz, M; Rogler, G; de Saussure, P; Sauter, B; Seibold, F; Straumann, A; Michetti, P (2010). Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: Results of the FACTS survey. Inflammatory Bowel Diseases, 16(6):933-938.

Pittet, V; Juillerat, P; Michetti, P; Vader, J P; Burnand, B; Rogler, G; Beglinger, C; Seibold, F; Mottet, C; Felley, C; Gonvers, J J; Froehlich, F; et al; Braegger, C P (2010). Appropriateness of therapy for fistulizing Crohn's disease: findings from a national inflammatory bowel disease cohort. Alimentary Pharmacology & Therapeutics, 32(8):1007-1016.

Schoepfer, A M; Beglinger, C; Straumann, A; Trummler, M; Vavricka, S R; Bruegger, L E; Seibold, F (2010). Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn's Disease (SES-CD) than CRP, blood leukocytes, and the CDAI. American Journal of Gastroenterology, 105(1):162-169.

Franke, A; McGovern, D P; Barrett, J C; Wang, K; Radford-Smith, G L; Ahmad, T; Lees, C W; Balschun, T; Lee, J; Roberts, R; Anderson, C A; Bis, J C; Bumpstead, S; Ellinghaus, D; Festen, E M; Georges, M; Green, T; Haritunians, T; Jostins, L; Latiano, A; Mathew, C G; Montgomery, G W; Prescott, N J; Raychaudhuri, S; Rotter, J I; Schumm, P; Sharma, Y; Simms, L A; Taylor, K D; Whiteman, D; Wijmenga, C; Baldassano, R N; Barclay, M; Bayless, T M; Brand, S; Büning, C; Cohen, A; Colombel, J F; Cottone, M; Stronati, L; Denson, T; De Vos, M; D'Inca, R; Dubinsky, M; Edwards, C; Florin, T; Franchimont, D; Gearry, R; Glas, J; Van Gossum, A; Guthery, S L; Halfvarson, J; Verspaget, H W; Hugot, J P; Karban, A; Laukens, D; Lawrance, I; Lemann, M; Levine, A; Libioulle, C; Louis, E; Mowat, C; Newman, W; Panés, J; Phillips, A; Proctor, D D; Regueiro, M; Russell, R; Rutgeerts, P; Sanderson, J; Sans, M; Seibold, F; Steinhart, A H; Stokkers, P C; Torkvist, L; Kullak-Ublick, G; Wilson, D; Walters, T; Targan, S R; Brant, S R; Rioux, J D; D'Amato, M; Weersma, R K; Kugathasan, S; Griffiths, A M; Mansfield, J C; Vermeire, S; Duerr, R H; Silverberg, M S; Satsangi, J; Schreiber, S; Cho, J H; Annese, V; Hakonarson, H; Daly, M J; Parkes, M (2010). Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nature Genetics, 42(12):1118-1125.

Juillerat, P; Pittet, V; Vader, J P; Burnand, B; Gonvers, J J; de Saussure, P; Mottet, C; Seibold, F; Rogler, G; Sagmeister, M; Felley, C; Michetti, P; Froehlich, F; et al; Braegger, C P (2010). Infliximab for Crohn's disease in the Swiss IBD Cohort Study: clinical management and appropriateness. European Journal of Gastroenterology & Hepatology, 22(11):1352-1357.

Beglinger, C; Binek, J; Braegger, C; Michetti, P; Rogler, G; Sauter, B; Seibold, F; Straumann, A (2008). Infliximab-Monotherapie versus Kombinationstherapie mit Immunmodulatoren : Aktuelle Therapieempfehlungen einer Schweizer Expertengruppe. Medical Journal (TMJ), (1):32-34.

This list was generated on Thu Jun 27 03:16:05 2019 CEST.